Cited by 279Amyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders ResearchAlzheimer's disease research and treatments

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models

Open access

McCampbell, Alex, Cole, Tracy, Wegener, Amy J., Tomassy, Giulio S., Setnicka, Amy, Farley, Brandon J., Schoch, Kathleen M., Hoye, Mariah L., Shabsovich, Mark, Sun, Linhong, Luo, Yi, Zhang, Mingdi, Thankamony, Sai, Salzman, David W., Cudkowicz, Merit, Graham, Danielle L., Bennett, C. Frank, Kordasiewicz, Holly B., Swayze, Eric E., Miller, Timothy M.·2018·Journal of Clinical Investigation

DOI 10.1172/jci99081PMC PMC6063493

Open this paper in CoChat — free account Open PDF

Abstract

Mutations in superoxide dismutase 1 (SOD1) are responsible for 20% of familial ALS. Given the gain of toxic function in this dominantly inherited disease, lowering SOD1 mRNA and protein is predicted to provide therapeutic benefit. An early generation antisense oligonucleotide (ASO) targeting SOD1 was identified and tested in a phase I human clinical trial, based on modest protection in animal models of SOD1 ALS. Although the clinical trial provided encouraging safety data, the drug was not advanced because there was progress in designing other, more potent ASOs for CNS application. We have developed next-generation SOD1 ASOs that more potently reduce SOD1 mRNA and protein and extend survival by more than 50 days in SOD1G93A rats and by almost 40 days in SOD1G93A mice. We demonstrated that the initial loss of compound muscle action potential in SOD1G93A mice is reversed after a single dose of SOD1 ASO. Furthermore, increases in serum phospho-neurofilament heavy chain levels, a promising biomarker for ALS, are stopped by SOD1 ASO therapy. These results define a highly potent, new SOD1 ASO ready for human clinical trial and suggest that at least some components of muscle response can be reversed by therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci99081

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Self-citation
Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury
Reaume, A. G., Elliott, J. L., Hoffman, E. K., Kowall, N. W., Ferrante, R. J., Siwek, D. F., Wilcox, H. M., Flood, D. G., Beal, M. F., Brown, R. H., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-43 · Cited by 1,285
Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S., Ohama, E., Reaume, A. G., Scott, R. W., & Cleveland, D. W. (1998) · Science · doi:10.1126/science.281.5384.1851 · Cited by 1,250
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citation
Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS
Bosco, D. A., Morfini, G. A., Karabacak, M., Song, Y., Gros‐Louis, F., Pasinelli, P., Goolsby, H., Fontaine, B. A., Lemay, N., McKenna-Yasek, D. M., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2660 · Cited by 685
Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion
Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K. M. G., Grant, S., Simpkinson, M., Bell, S., Carmona, S., Ornelas, L., Sahabian, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007529 · Cited by 670
Self-citation
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citation
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration
Lagier‐Tourenne, C., Baughn, M. W., Rigo, F., Sun, S., Liu, P., Li, H., Jiang, J., Watt, A. T., Chun, S. J., Katz, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318835110 · Cited by 585
Self-citation

Show all 46 references

Sorted by citations

Items 101–200 of 279

Amyotrophic lateral sclerosis
Younger, D. S., & Brown, R. H. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98817-9.00031-4 · Cited by 35
Efficacy and safety of a SOD1-targeting artificial miRNA delivered by AAV9 in mice are impacted by miRNA scaffold selection
Chen, S. K., Hawley, Z. C. E., Zavodszky, M. I., Hana, S., Ferretti, D., Grubor, B., Hawes, M. C., Xu, S., Hamann, S., Marsh, G., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102057 · Cited by 27
Patient and Relative Experiences and Decision-making About Genetic Testing and Counseling for Familial ALS and FTD
Crook, A., Jacobs, C., Newton-John, T. R. O., Richardson, E., & McEwen, A. (2021) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000458 · Cited by 27
Intercellular transmission of pathogenic proteins in ALS: Exploring the pathogenic wave
Arnold, F. J., Nguyen, A., Bedlack, R., Bennett, C. L., & Spada, A. R. L. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106218 · Cited by 29
Self-citation
Current application of neurofilaments in amyotrophic lateral sclerosis and future perspectives
Falzone, Y. M., Russo, T., Domi, T., Pozzi, L., Quattrini, A., Filippi, M., & Riva, N. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308072 · Cited by 27
Potential of Cellular Therapy for ALS: Current Strategies and Future Prospects
Lin, T.-J., Cheng, K.-C., Wu, L.-Y., Lai, W.-Y., Ling, T., Kuo, Y., & Huang, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.851613 · Cited by 26
Premature termination codons in SOD1 causing Amyotrophic Lateral Sclerosis are predicted to escape the nonsense-mediated mRNA decay
Guissart, C., Mouzat, K., Kantar, J., Louveau, B., Vilquin, P., Polge, A. S., Raoul, C., & Lumbroso, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-77716-5 · Cited by 24
Early death of ALS-linked CHCHD10-R15L transgenic mice with central nervous system, skeletal muscle, and cardiac pathology
Ryan, É. B., Yan, J., Miller, N., Dayanidhi, S., Ma, Y. C., Deng, H., & Siddique, T. (2021) · iScience · doi:10.1016/j.isci.2021.102061 · Cited by 24
Therapeutic Development for CGG Repeat Expansion-Associated Neurodegeneration
Xu, K., Li, Y., Allen, E. G., & Jin, P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.655568 · Cited by 25
Targeting the NEDP1 enzyme to ameliorate ALS phenotypes through stress granule disassembly
Kassouf, T., Shrivastava, R., Meszka, I., Bailly, A., Polanowska, J., Trauchessec, H., Mandrioli, J., Carra, S., & Xirodimas, D. P. (2023) · Science Advances · doi:10.1126/sciadv.abq7585 · Cited by 24
Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis
Nguyen, L. (2024) · Cells · doi:10.3390/cells13110888 · Cited by 29
Prospects for gene replacement therapies in amyotrophic lateral sclerosis
Giovannelli, I., Higginbottom, A., Kirby, J., Azzouz, M., & Shaw, P. J. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00751-5 · Cited by 23
Intrathecal administration of a novel siRNA modality extends survival and improves motor function in the SOD1G93A ALS mouse model
Duan, C., Kang, M., Pan, X., Gan, Z., Huang, V., Li, G., Place, R. F., & Li, L. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102147 · Cited by 26
Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen
Moriyama, H., & Yokota, T. (2024) · Genes · doi:10.3390/genes15101342 · Cited by 24
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients
Xie, Q., Li, K., Chen, Y., Li, Y., Jiang, W., Cao, W., Yu, H., Fan, D., & Deng, B. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00477-6 · Cited by 27
A Review of Biomarkers of Amyotrophic Lateral Sclerosis: A Pathophysiologic Approach
Alshehri, R. S., Abuzinadah, A. R., Alrawaili, M. S., Alotaibi, M. K., Alsufyani, H. A., Alshanketi, R. M., & Alshareef, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010900 · Cited by 23
An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis
Gertsman, I., Wuu, J., McAlonis‐Downes, M., Ghassemian, M., Ling, K., Rigo, F., Bennett, F., Benatar, M. G., Miller, T. M., & Cruz, S. D. (2019) · JCI Insight · doi:10.1172/jci.insight.122768 · Cited by 23
Self-citation
The prion-like nature of amyotrophic lateral sclerosis
McAlary, L., Yerbury, J. J., & Cashman, N. R. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.07.002 · Cited by 21
Nuclear pore dysfunction and disease: a complex opportunity
Fare, C. M., & Rothstein, J. D. (2024) · Nucleus · doi:10.1080/19491034.2024.2314297 · Cited by 21
An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement
Poplawski, S. G., Garbett, K. A., McMahan, R. L., Kordasiewicz, H. B., Zhao, H. T., Kennedy, A. J., Goleva, S. B., Sanders, T. H., Motley, S. T., Swayze, E. E., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.01.027 · Cited by 21
Self-citation
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease
Ou, K., Jia, Q., Li, D., Li, S., Li, X., & Yin, P. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00466-9 · Cited by 23
Tofersen and other antisense oligonucleotides in ALS
Ludolph, A., & Wiesenfarth, M. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251313915 · Cited by 19
Oligonucleotide-based therapeutics for neurodegenerative disorders: Focus on antisense oligonucleotides
Mansour, H. M., & El-Khatib, A. S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177529 · Cited by 20
Selective removal of misfolded SOD1 delays disease onset in a mouse model of amyotrophic lateral sclerosis
Guan, T., Zhou, T., Zhang, X., Guo, Y., Yang, C., Lin, J. J., Zhang, J. V., Cheng, Y., Marzban, H., Wang, Y. T., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04956-9 · Cited by 20
Antisense therapy: a potential breakthrough in the treatment of neurodegenerative diseases
Romanò, R., & Bucci, C. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385285 · Cited by 21
FUS gene mutation in amyotrophic lateral sclerosis: a new case report and systematic review
Xiao, X., Li, M., Ye, Z., He, X., Wei, J. S., & Zha, Y. (2023) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2023.2272170 · Cited by 21
Specific Expression of Glial-Derived Neurotrophic Factor in Muscles as Gene Therapy Strategy for Amyotrophic Lateral Sclerosis
Mòdol‐Caballero, G., García-Lareu, B., Herrando‐Grabulosa, M., Verdés, S., López‐Vales, R., Pagès, G., Chillón, M., Navarro, X., & Bosch, A. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01025-6 · Cited by 20
RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice
Weiss, A., Gilbert, J. W., Flores, I. V. R., Belgrad, J., Ferguson, C. M., Dogan, E. O., Wightman, N., Mocarski, K., Echeverria, D., Harkins, A. L., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.010 · Cited by 20
Antisense oligonucleotides targeting Notch2 ameliorate the osteopenic phenotype in a mouse model of Hajdu-Cheney syndrome
CANALIS, E. M., Grossman, T. R., Carrer, M., Schilling, L., & Yu, J. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011440 · Cited by 18
Reduction of nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43–related neurodegeneration
Tejwani, L., Jung, Y., Kokubu, H., Sowmithra, S., Ni, L., Lee, C., Sanders, B., Lee, P. J., Xiang, Y., Luttik, K., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci138207 · Cited by 17
“been the disease-causing protein itself (33, 42-45).”
Clinical features and progress in diagnosis and treatment of amyotrophic lateral sclerosis
Yuan, D., Jiang, S., & Xu, R. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2399962 · Cited by 17
Tofersen: A Review in Amyotrophic Lateral Sclerosis Associated with SOD1 Mutations
McGuigan, A., & Blair, H. A. (2025) · CNS Drugs · doi:10.1007/s40263-025-01204-5 · Cited by 21
MicroRNA expression in animal models of amyotrophic lateral sclerosis and potential therapeutic approaches
Peplow, P., & Martinez, B. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.322431 · Cited by 16
Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis
Hergesheimer, R. C., Lanznaster, D., Vourc’h, P., Andres, C. R., Bakkouche, S. E., Beltran, S., Blasco, H., Corcia, P., & Couratier, P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1746270 · Cited by 17
Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?
Alarcan, H., Ojaimi, Y. A., Lanznaster, D., Escoffre, J., Corcia, P., Vourc’h, P., Andres, C. R., Veyrat‐Durebex, C., & Blasco, H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071071 · Cited by 17
The Beginning of Genomic Therapies for ALS
Hardiman, O. M., & van den Berg, L. H. (2020) · New England Journal of Medicine · doi:10.1056/nejme2012930 · Cited by 16
Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce α-synuclein in a mouse model of Alzheimer's disease
Leitao, A. D. G., Ahammad, R. U., Spencer, B. J., Wu, C., Masliah, E., & Rissman, R. A. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106285 · Cited by 16
Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS
Lee, S. Y., Cho, H.-Y., Oh, J.-P., Park, J., Bae, S.-H., Park, H., Kim, E. J., & Lee, J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01444-7 · Cited by 21
Dual Role of Lysophosphatidic Acid Receptor 2 (LPA2) in Amyotrophic Lateral Sclerosis
Puigdomenech, M., Martínez‐Muriana, A., Andrés‐Benito, P., Ferrer, I., Chun, J. J. M., & López‐Vales, R. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.600872 · Cited by 16
RNA Engineering for Public Health: Innovations in RNA-Based Diagnostics and Therapeutics
Thavarajah, W., Hertz, L. M., Bushhouse, D. Z., Archuleta, C. M., & Lucks, J. B. (2021) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101420-014055 · Cited by 15
Mitochondrial Dysfunction in Aging: Future Therapies and Precision Medicine Approaches
Jia, L., Wei, Z., Luoqian, J., Wang, X., & Huang, C. (2025) · MedComm – Future Medicine · doi:10.1002/mef2.70026 · Cited by 14
Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathy
Nakayama, T., Achkar, C. M. E., Burbano, L. E., Quraishi, I. H., Wu, J. S., Li, M. J., Asami, Y., Golinski, S. R., Sherrill, E., Goodlett, B. D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04314-9 · Cited by 17
AAV-NRIP gene therapy ameliorates motor neuron degeneration and muscle atrophy in ALS model mice
Chen, H.-H., Yeo, H.-T., Huang, Y.-H., Tsai, L.-K., Lai, H.-J., Tsao, Y.-P., & Chen, S.-L. (2024) · Skeletal Muscle · doi:10.1186/s13395-024-00349-z · Cited by 14
Investigating RFC1 expansions in sporadic amyotrophic lateral sclerosis
Abramzon, Y., Dewan, R., Cortese, A., Resnick, S. M., Ferrucci, L., Houlden, H., & Traynor, B. J. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.118061 · Cited by 15
Astrocyte‐targeting RNA interference against mutated superoxide dismutase 1 induces motoneuron plasticity and protects fast‐fatigable motor units in a mouse model of amyotrophic lateral sclerosis
Rochat, C., Bernard‐Marissal, N., Källstig, E., Pradervand, S., Perrin, F. E., Aebischer, P., Raoul, C., & Schneider, B. L. (2022) · Glia · doi:10.1002/glia.24140 · Cited by 13
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
Chen, Y., Mazur, C., Luo, Y., Sun, L., Zhang, M., McCampbell, A., & Tomassy, G. S. (2019) · Journal of Visualized Experiments · doi:10.3791/60274 · Cited by 15
Self-citation
Promising animal models for amyotrophic lateral sclerosis drug discovery: a comprehensive update
Lescouzères, L., & Patten, S. A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2387791 · Cited by 16
The Skeleton of Lateral Meningocele Syndrome
CANALIS, E. M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.620334 · Cited by 13
Amyotrophic lateral sclerosis: exploring pathophysiology in the context of treatment
Genge, A. L., Wainwright, S., & Velde, C. V. (2023) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2023.2278503 · Cited by 13
Modeling ALS with Patient-Derived iPSCs: Recent Advances and Future Potentials
Nejad, L. D., & Pioro, E. P. (2025) · Brain Sciences · doi:10.3390/brainsci15020134 · Cited by 13
Hereditary Motor Neuropathies and Amyotrophic Lateral Sclerosis: a Molecular and Clinical Update
García-Santibáñez, R., Burford, M. J., & Bucelli, R. C. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0901-z · Cited by 14
HuD impairs neuromuscular junctions and induces apoptosis in human iPSC and Drosophila ALS models
Silvestri, B., Mochi, M., Mawrie, D., de Turris, V., Colantoni, A., Borhy, B., Medici, M., Anderson, E. N., Garone, M. G., Zammerilla, C. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54004-8 · Cited by 11
Simple In-Cell Processing Enables Deep Proteome Analysis of Low-Input Caenorhabditis elegans
Elsayyid, M. W., Tanis, J. E., & Yu, Y. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c05003 · Cited by 13
Modeling central nervous system disorders in zebrafish: Novel insights into pathophysiology and therapeutic discovery
Meng, X., Yang, L., Liao, Z., Sun, F., Su, M., & Mei, Z. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107123 · Cited by 11
The Timing and Extent of Motor Neuron Vulnerability in ALS Correlates with Accumulation of Misfolded SOD1 Protein in the Cortex and in the Spinal Cord
Genç, B., Gözütok, Ö., Koçak, N., & Özdi̇nler, P. H. (2020) · Cells · doi:10.3390/cells9020502 · Cited by 11
Gene therapy successes point to better therapies
Dolgin, E. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918306116 · Cited by 11
Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders
Bizot, F., Vulin, A., & Goyenvalle, A. (2020) · Drugs · doi:10.1007/s40265-020-01363-3 · Cited by 12
CK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis
Ko, V. I., Ong, K., Kwon, D. Y., Li, X., Pietrasiewicz, A., Harvey, J. S., Lulla, M., Bhat, G., Cleveland, D. W., & Ravits, J. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01902-z · Cited by 10
Protein production is an early biomarker for RNA ‐targeted therapies
Self, W. K., Schoch, K. M., Alex, J., Barthélemy, N. R., Bollinger, J. G., Sato, C., Cole, T. A., Kordasiewicz, H. B., Swayze, E. E., Bateman, R. J., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.657 · Cited by 9
Self-citation
Targeted ASO-mediated Atp1a2 knockdown in astrocytes reduces SOD1 aggregation and accelerates disease onset in mutant SOD1 mice
Iyer, A. K., Schoch, K. M., Verbeck, A. C., Galasso, G., Chen, H., Smith, S. E., Oldenborg, A., Miller, T. M., Karch, C. M. M., & Bonni, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294731 · Cited by 9
Self-citation
Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Singh, M., Singh, S. P., Yadav, D., Agarwal, M., Agarwal, S., Agarwal, V., Swargiary, G., Srivastava, S., Tyagi, S., Kaur, R., et al. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200817164907 · Cited by 9
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease
Strnad, P., & Martín, J. S. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2239707 · Cited by 9
Prion protein lowering is a disease-modifying therapy across prion disease stages, strains, and endpointsPreprint
Minikel, E. V., Zhao, H. T., Le, J., O’Moore, J., Pitstick, R., Graffam, S., Carlson, G. A., Kavanaugh, M. P., Križ, J., Kim, J. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.27.011940 · Cited by 10
Self-citation
A new diagnostic entity must enable earlier treatment in gene carriers
Swidler, J., Olson, T., Edelstein, A. L., Granning, J., Haddad, C., Uhrlaub, M., & Wicks, P. J. (2023) · Brain · doi:10.1093/brain/awad164 · Cited by 9
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Crossing Barriers: Advancements in Macromolecular Therapeutics for Neurodegenerative Diseases and Strategies to Overcome the Blood–Brain Barrier
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 10
RNA-Based Therapies for Neurodegenerative Diseases.
Ayala, Y. M., & Nguyen, A. D. (2021) · PubMed Central · Cited by 8
Repeat-associated non-AUG translation as a common mechanism for the polyGln ataxias
Báñez-Coronel, M., Zu, T., Aldridge, M., Guo, S., Ajredini, R., Morrison, D., Tays, A. B., Duvick, L. A., Pletniková, O., Yachnis, A. T., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116741 · Cited by 7
Unraveling and controlling late-onset neurotoxicity of antisense oligonucleotides through strategic chemical modifications
Kuroda, T., Yoshioka, K., Mon, S. S. L., Katsuyama, M., Sato, K., Isogai, E., Yoshida‐Tanaka, K., Iwata-Hara, R., Yamaguchi, T., Obika, S., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102692 · Cited by 9
Antisense-Therapie neurologischer Erkrankungen
Pulst, S. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0724-4 · Cited by 9
Cortical projection neurons as a therapeutic target in multiple sclerosis
Beutel, T., Dzimiera, J., Kapell, H., Engelhardt, M., Gass, A., & Schirmer, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1842358 · Cited by 7
Analysis of non-human primate models for evaluating prion disease therapeutic efficacy
Mortberg, M. A., Minikel, E. V., & Vallabh, S. M. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010728 · Cited by 8
Combining electromyography and Raman spectroscopy: optical EMG
Alix, J. J. P., Plesia, M., Shaw, P. J., Mead, R. J., & Day, J. C. C. (2023) · Muscle & Nerve · doi:10.1002/mus.27937 · Cited by 7
DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs
Ohara, M., Nagata, T., Kuwahara, H., Yoshida‐Tanaka, K., Toide, N., Takagi, K., Sato, K., Takenaka, T., Nakakariya, M., Miyata, K., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102289 · Cited by 6
Site-blocking antisense oligonucleotides as a mechanism to fine-tune MeCP2 expression
Vanderplow, A. M., Dodis, G. E., Rhee, Y., Cikowski, J., Gonzalez, S., Smith, M. L., & Gogliotti, R. G. (2024) · RNA · doi:10.1261/rna.080220.124 · Cited by 6
In vivo self-assembled SOD1-siRNAs mitigate muscle atrophy and denervation in amyotrophic lateral sclerosis
Guo, J., Zou, Q., Xu, J., Lei, J., Yin, X., Li, B., Fu, J., Mi, J., Wang, Y., Huang, H., et al. (2025) · Brain · doi:10.1093/brain/awaf291 · Cited by 6
Targeting Amyotrophic Lateral Sclerosis with Gene Therapy: From Silencing Genes to Enhancing Neuroprotection
Verdés, S., Navarro, X., & Bosch, A. (2025) · Human Gene Therapy · doi:10.1177/10430342251372898 · Cited by 8
Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial
Chen, W., Jiang, L., Duan, C., Kang, M., Ye, J., Wang, L., Pan, Y., Qu, H., Liao, X., Zhou, X., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04491-7 · Cited by 6
Central Nervous System Biodistribution and Pharmacokinetics of Radiolabeled Tofersen in Rodents, Nonhuman Primates, and Humans
Cook, B. E., McLaren, D. G., Sullivan, J. M., Fakhri, G. E., Yokell, D. L., Freeman, M. W., Currier, N. V., Oestergaard, M. E., Dobson, H., Hesterman, J. Y., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270731 · Cited by 6
Self-citation
Protein Assembly Modulation: A New Approach to Amyotrophic Lateral Sclerosis (ALS) Therapeutics
Yu, S. F., Paulvannan, K., Solas, D., Lingappa, A. F., Moreira, A. R., Sahu, S., Michon, M., Macieik, A., Goldsmith, D., DeYarman, N., et al. (2024) · Journal of Experimental Neurology · doi:10.33696/neurol.5.103 · Cited by 5
Self-citation
Amyotrophe Lateralsklerose – ein Update zu Diagnostik, Therapie und Forschung
Witzel, S., & Ludolph, A. C. (2019) · Neurologie up2date · doi:10.1055/a-0865-3953 · Cited by 4
Barriers to Tofersen Therapy for Variant SOD1 -Mediated ALS
Appel, S. H., & Thonhoff, J. R. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3331 · Cited by 5
Experimental Models in Neurodegenerative Diseases
Korkmaz, Ü., & Kaya, M. (2019) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2019.0009 · Cited by 5
Save Your Maximum Tolerated Dose: How to Diagnose Procedure-Related Spinal Cord Lesions After Lumbar Intrathecal Bolus Administration of Oligonucleotides in Cynomolgus Monkeys
Korte, S., Luft, J., von Keutz, A., Runge, F., Mecklenburg, L., Woźniak, M. M., Zander, S. A. L., Ludwig, F. T., Pajaziti, B., Romeike, A., et al. (2020) · International Journal of Toxicology · doi:10.1177/1091581820951098 · Cited by 5
Use of antisense oligonucleotides to target Notch3 in skeletal cells
CANALIS, E. M., Carrer, M., Eller, T., Schilling, L., & Yu, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268225 · Cited by 5
Genspezifische Therapieansätze bei amyotropher Lateralsklerose in Gegenwart und Zukunft
Brenner, D., Freischmidt, A., Ludolph, A., & Weishaupt, J. H. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-00873-5 · Cited by 6
Pan-Asian consortium for treatment and research in ALS (PACTALS) guidelines for management of amyotrophic lateral sclerosis
Vucic, S., Shahrizaila, N., Kano, O., Menon, P., Agustini, S., Kulkantrakorn, K., Nalini, A., Lee, Y., Prado, M. B., Ng, K. W. P., et al. (2025) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2025.101684 · Cited by 6
Translating the ALS Genetic Revolution into Therapies: A Review
Meadows, C., Rau, N. A., Faridi, W., & Ly, C. V. (2024) · Current Treatment Options in Neurology · doi:10.1007/s11940-024-00781-y · Cited by 4
Construction of a rodent neural network-skeletal muscle assembloid that simulate the postnatal development of spinal cord motor neuronal network
Yu, H., Yang, S., Chen, Y., Wu, C., Xu, J., Yang, Y., Wu, R., Guo, Y., Chen, Z., Ding, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-88292-x · Cited by 4
A polytherapy approach demonstrates therapeutic efficacy for the treatment of SOD1 associated amyotrophic lateral sclerosis
Lum, J. S., Brown, M. L., Farrawell, N. E., Bartlett, R., Chisholm, C. G., Gorman, J., Dosseto, A., Dux, F. W., McInnes, L. E., Ecroyd, H. W., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105692 · Cited by 4
Antisense Oligonucleotide Therapeutics for Neurodegenerative Disorders
Testa, C. M. (2021) · Current Geriatrics Reports · doi:10.1007/s13670-020-00341-7 · Cited by 4
Virus-like siRNA construct dynamically responsive to sequential microenvironments for potent RNA interference
Wang, Y., Zheng, X., Liu, J., Chen, L., Chen, Q., & Zhao, Y. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.05.006 · Cited by 4
Genetically modified animal models of hereditary diseases for testing of gene-directed therapy
Polikarpova, A. V., Egorova, T. V., & Bardina, M. V. (2022) · Research Results in Pharmacology · doi:10.3897/rrpharmacology.8.82618 · Cited by 8
Customized antisense oligonucleotide-based therapy for neurofilament-associated Charcot–Marie–Tooth disease
Medina, J., Rebelo, A. P., Danzi, M. C., Jacobs, E. H., Xu, I. R. L., Ahrens, K. P., Chen, S., Raposo, J. S., Yanick, C., Zuchner, S. L., et al. (2024) · Brain · doi:10.1093/brain/awae225 · Cited by 6
Amide signal intensities may be reduced in the motor cortex and the corticospinal tract of ALS patients
Dai, Z., Kalra, S., Mah, D., Seres, P., Sun, H., Wu, R., & Wilman, A. H. (2020) · European Radiology · doi:10.1007/s00330-020-07243-4 · Cited by 4
Neuroglia in neurodegeneration: Amyotrophic lateral sclerosis and frontotemporal dementia
Marchi, F. D., Spinelli, E. G., & Bendotti, C. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19102-2.00004-1 · Cited by 4
Inhibition of SOD1 trimerization is a novel drug target for ALS disease
Woo, T., Han, J., Kim, Y., Hwang, Y. J., Lee, M. G., Kang, S., Park, S., Ji, Y., Chung, Y., Baek, S., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00483-8 · Cited by 3
Genetic therapies for neurological diseases
Rahim, A. A., Kurian, M. A., Zhou, H., Ferguson, R., Tabrizi, S. J., Lignani, G., Aquilina, K., & Waddington, S. N. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100093 · Cited by 4
Positive modulation of sigma-1 receptor: a new weapon to mitigate disease progression in amyotrophic lateral sclerosis
Friec, J. L., Mourier, H., Couly, S., Cubedo, N., Dubois, K., Meunier, J., Delprat, B., de Zordo‐Banliat, A., Ayad, T., Virieux, D., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00527-z · Cited by 3
New developments in pre-clinical models of ALS to guide translation
Cock, L. D., Bercier, V., & Bosch, L. V. D. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.04.008 · Cited by 3

Authors: McCampbell, A., Cole, T., Wegener, A. J., Tomassy, G. S., Setnicka, A., Farley, B. J., Schoch, K. M., Hoye, M. L., Shabsovich, M., Sun, L., Luo, Y., Zhang, M., Thankamony, S., Salzman, D. W., Cudkowicz, M., Graham, D. L., Bennett, C. F., Kordasiewicz, H. B., Swayze, E. E., & Miller, T. M.
Affiliations: Biogen (United States) (US)
Ionis Pharmaceuticals (United States) (US)
Washington University in St. Louis (US)
Harvard University (US)
Corresponding author: Miller, Timothy M.
ORCID: Wegener, Amy J.
Farley, Brandon J.
Schoch, Kathleen M.
Hoye, Mariah L.
Luo, Yi
Salzman, David W.
Cudkowicz, Merit
Graham, Danielle L.
Bennett, C. Frank
Kordasiewicz, Holly B.
Swayze, Eric E.
Miller, Timothy M.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2018-07-16
Volume: 128
Issue: 8
Pages: 3558-3567
ISSN: 0021-9738 (ISSN-L)
1558-8238
DOI: 10.1172/jci99081
PMC: PMC6063493
OpenAlex: W2884390718
Cited by: 279
References: 46
Citations by year: 2026: 30 · 2025: 36 · 2024: 48 · 2023: 35 · 2022: 32 · 2021: 30 · 2020: 42 · 2019: 22 · 2018: 4
FWCI: 16.64
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
Funders: Biogen
Ionis Pharmaceuticals
National Institutes of Health (50 and)
National Institute of Neurological Disorders and Stroke (U01NS084970, R01NS078398)
Topics: Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: antisense oligonucleotides, amyotrophic lateral sclerosis, SOD1, SOD1 G93A mice, familial ALS, compound muscle action potential, neurofilament heavy chain, biomarkers, survival extension, ALS therapeutics
MeSH terms: Superoxide Dismutase-1, Amyotrophic Lateral Sclerosis, Animals, Disease Models, Animal, Humans, Superoxide Dismutase, Muscle, Skeletal, Oligodeoxyribonucleotides, Antisense, Rats, Rats, Transgenic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks